KWIZERA CHANTAL (NL)
BLOK SIMON NIELS (NL)
FARINHA ANTUNES INES (NL)
ELSINGA PHILIPPUS HEIN (NL)
DE VRIES ERIK (NL)
ACADEMISCH ZIEKENHUIS GRONINGEN (NL)
WO2015058047A2 | 2015-04-23 | |||
WO2019186135A1 | 2019-10-03 | |||
WO2015058047A2 | 2015-04-23 | |||
WO2019186135A1 | 2019-10-03 |
US20050137421A1 | 2005-06-23 | |||
US20050137421A1 | 2005-06-23 |
EDWARDS RICHARD ET AL: "Convenient Synthesis of Diaryliodonium Salts for the Production of [ 18 F]F-DOPA : Diaryliodonium Salts for the Production of [ 18 F]F-DOPA", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, vol. 2015, no. 3, 1 January 2015 (2015-01-01), DE, pages 625 - 630, XP093024299, ISSN: 1434-193X, DOI: 10.1002/ejoc.201403378
DE VRIES ET AL., APPL RADIAT ISOT, vol. 51, 1999, pages 389 - 94
JIANG ET AL., AM J NUCL MED MOL IMAGING, vol. 11, no. 4, 15 August 2021 (2021-08-15), pages 290 - 299
ANDERSEN ET AL., EJNMMI RADIOPHARM CHEM, vol. 6, no. 1, 12 June 2021 (2021-06-12), pages 21
KRASIKOVA, MOLECULES, vol. 25, no. 19, 23 September 2020 (2020-09-23), pages 4365
KUCI ET AL., LABELLED COMP RADIOPHARM, vol. 62, no. 8, 30 June 2019 (2019-06-30), pages 438 - 447
MOSSINE ET AL., NAT PROTOC, vol. 15, no. 5, May 2020 (2020-05-01), pages 1742 - 1759
MAKARAVAGE ET AL., ORG. LETT, vol. 18, no. 20, 21 October 2016 (2016-10-21), pages 5440 - 5443
EDWARDS ET AL., EUR. J. ORG. CHEM., vol. 2015, no. 3, 1 January 2015 (2015-01-01), pages 625 - 630
ZARRAD ET AL., MOLECULES, vol. 22, 2017, pages 2231 - 2255
MAKARAVAGE ET AL., ORG. LETT., vol. 18, no. 20, 21 October 2016 (2016-10-21), pages 5440 - 5443
GUIBBAL ET AL., MOL IMAGING BIOL, vol. 22, no. 5, 2020, pages 1226 - 1234
NATURE PROTOCOLS, vol. 15, no. 4
WILSON ET AL., J NUCL MED, vol. 60, no. 4, April 2019 (2019-04-01), pages 504 - 510
Claims 1. A method for the one-pot synthesis of 6-L-[18F]fluoro-3,4- dihydroxyphenylalanine (6-L-[18F]FDOPA) involving the Cu-mediated 18F- fluorodestannylation of a BOC- protected stannyl precursor, comprising the steps of: (i) contacting a BOC- protected stannyl precursor of the formula I with [18F]Tetraethylammonium fluoride ([18F]Et4NF) in the presence of the Cu-catalyst Cu(imidazo[1,2-b]pyridazine)4(OTf)2 to yield the 18F- labeled BOC-protected intermediate compound of the formula II ; and (ii) hydrolyzing the [18F] BOC-protected intermediate compound using HCl to obtain 6-L-[18F]fluoro-3,4-dihydroxyphenylalanine (6-L-[18F]FDOPA). 2. Method according to claim 1, wherein the BOC- protected stannyl precursor is N,N,O,O’-tetra-BOC-6-(SnMe3)DOPA-OMe. 3. Method according to claim 2, comprising prior to step (i) preparing N,N,O,O’-tetra-BOC-6-(SnMe3)DOPA-OMe by N-BOC protection of N,O,O’- tri-BOC-6-(SnMe3)DOPA-OMe. 4. Method according to any one of claims 1-3, wherein step (i) is performed in the presence of dimethylacetamide (DMA) and n-butanol. 5. Method according to any one of claims 1-4 wherein step (i) is performed at a temperature in the range of about 130-150 ºC, preferably at around 140ºC. 6. Method according to any one of the preceding claims, wherein the molar ratio of BOC-protected stannyl precursor / Cu(imidazo[1,2-b]- pyridazine)4(OTf)2 is in the range of 2:3 to 1:2, preferably about 1:1.5 to 1:2. 7. Method according to any one of the preceding claims, wherein step (ii) is performed in the presence of an anti-oxidant, preferably ascorbic acid. 8. Method according to any one of the preceding claims, to provide 6-L- [18F]FDOPA in a radiochemical conversion (RCC) of at least 50%. 9. A cassette for carrying out a one-pot synthesis of 6-L-[18F]fluoro-3,4- dihydroxyphenylalanine (6-L-[18F]FDOPA), comprising: (i) a BOC- protected stannyl precursor of Formula I as defined in Claim 1 or 2; and Cu(imidazo[1,2-b]pyridazine)4(OTf)2, wherein said precursor and said Cu(imidazo[1,2- b]pyridazine)4(OTf)2 may be present in the same vessel or in separate vessels, preferably wherein said precursor and said Cu(imidazo[1,2-b]pyridazine)4(OTf)2 are present as pre- mixture in the same vessel. 10. The cassette according to claim 9, further comprising (ii) a separate vessel containing a solution of a tetraethylammonium salt, preferably selected from the group consisting of Et4NHCO3, Et4NOTf, Et4NF4 and Et4NI. 11. The cassette according to claim 9 or 10, wherein said BOC- protected stannyl precursor is N,N,O,O’-tetra-BOC-6-(SnMe3)DOPA-OMe. 12. The cassette according to any one of claims 9-11, further comprising (iii) a separate vessel comprising a solution of HCl. 13. The cassette according to claim 12, comprising (i) a vessel comprising a solution of Et4NHCO3 (ii) a vessel comprising N,N,O,O’-tetra-BOC-6-(SnMe3)DOPA-OMe and Cu(imidazo[1,2-b]pyridazine)4(OTf)2 (iii) a vessel comprising a solution comprising HCl and ascorbic acid. 14. A device for automated synthesis of a radioactive tracer, the device comprising a fixed module and a disposable module which is positioned on the fixed module, the fixed module comprising a processor and an interface for the disposable module, and wherein the disposable module comprises a cassette according to any one of claims 9-13. 15. A reaction mixture comprising N,N,O,O’-tetra-BOC-6- (SnMe3)DOPA-OMe, Cu(imidazo[1,2-b]pyridazine)4(OTf)2 and [18F]Tetraethylammonium fluoride in a solvent, preferably in DMA comprising n-butanol. |
EXPERIMENTAL SECTION EXAMPLE 1: Manufacture of [ 18 F]Et4NF. A target filled with 2 mL enriched water (H2 18 O) was bombarded with protons using a medical 18 MeV cyclotron. After approx.30 GBq of [ 18 F]fluoride was produced, the target was unloaded, and the enriched water containing [ 18 F]fluoride was transported via tubings to the radiopharmaceutical production facility in to a hotcell, in which it was collected in a conical vial. After collection, H2 18 O containing [ 18 F]fluoride was aspirated by the Synthera V2 synthesis module and [ 18 F]fluoride was trapped onto a Waters® Sep-Pak Accell Plus QMA Carbonate Plus Light Cartridge that was conditioned with 1 mL of water. The cartridge was flushed with 2 mL of methanol and dried using a nitrogen stream for five minutes. The [ 18 F]fluoride was eluted from the cartridge into the reactor using Et4NHCO3 (5 mg, 26.1 µmol) in 1 mL of methanol. The cartridge was flushed for one minute using a nitrogen stream. The contents of the reactor were then concentrated to dryness by heating the reactor to 90 °C under reduced pressure for five minutes to yield the dried [ 18 F]Et4NF. EXAMPLE 2: Manufacture of Cu(Impy)4(OTf)2. The copper catalyst was prepared based on published methods. See Wilson et al. (J Nucl Med.2019 Apr; 60(4): 504–510). Briefly, a solution of imidazo[1,2-b]pyridazine (Impy) (758 mg, 6.36 mmol, 10 equiv.) in MeOH (1 mL) was added dropwise at 55°C to a solution of Cu(OTf) 2 (230 mg, 0.636 mmol, 1.0 equiv.) in MeOH (1 mL). The blue precipitate which formed was washed with Et2O (3 x 2 mL), then recrystallized from hot MeOH to afford [Cu(Impy) 4 (OTf) 2 ] (324 mg, 0.387 mmol, 61%). EXAMPLE 3: One-pot synthesis of 6-L-[ 18 F]FDOPA. A reaction mixture was prepared comprising [ 18 F]Et4NF according to Example 1, a solution of the BOC-protected stannyl precursor N,N,O,O’- tetra-BOC-6-(SnMe 3 )DOPA-OMe (8 mg, 10.3 µmol; ABX advanced biochemical compounds GmbH, Radeberg, Germany) and Cu(Impy)4(OTf)2 (14 mg, 16.7 µmol) in 900 µL DMA and 100 µL n-butanol. This reaction mixture was heated to 140 °C for 30 minutes. The reactor was cooled down to 50 °C prior to the addition of a deprotecting solution containing 6 M HCl (800 µL, 4.8 mmol) and 0.25 M ascorbic acid solution (200µL, 50 µmol). The deprotection reaction was heated to 120 °C and allowed to proceed for 20 minutes, after which the solution was diluted to a total volume of 2 mL by addition of water. The mixture was filtered over a Waters® Sep-Pak Alumina B Plus Light Cartridge, followed by a Pall Acrodisc 1.2 µm filter and injected on HPLC for product characterization. EXAMPLE 4: Conversion analysis by TLC. The radiochemical conversion is calculated from the intensity of the spots on TLC. Division of the signal of BOC-protected 6-L-[ 18 F]FDOPA by the total signal of all radioactive compounds present on the lane of the TLC plate gives the percentage of [ 18 F]fluoride converted to BOC-protected 6-L- [ 18 F]FDOPA (Lane%). EXAMPLE 5: Product analysis by HPLC. The calculated radiochemical yield of the reaction is calculated from the integration of radioactive peaks. The relative peak area of the 6-L- [ 18 F]FDOPA peak is divided compared to the total area of all radioactive peaks combined gives the percentage of [ 18 F]fluoride converted to 6-L- [ 18 F]FDOPA (% Area). EXAMPLE 6: Comparative testing of Cu catalyst or anti-oxidant. Table 1 below illustrates the advantages of using the copper catalyst Cu(Impy) 4 (OTf) 2 according to a method of the invention as compared to catalyst containing no or different Cu(II) complexing ligands e.g. in Cu(OTf)2 and Cu(Py)4(OTf)2. Reaction mixtures and conditions were as described herein above using the BOC-protected stannyl precursor N,N,O,O’-tetra-BOC-6-(SnMe3)DOPA-OMe (8 mg, 10.3 µmol; ABX advanced biochemical compounds GmbH, Radeberg, Germany) and Cu-catalyst (16.7 µmol) in DMA/n-butanol. The comparative experiment was performed 4 times, each of which demonstrating that the highest conversion was obtained using Cu(Impy)4(OTf)2. Table 1 : Conversion (%) Table 2 below illustrates the advantages of including ascorbic acid (0.25 M) as anti-oxidant in the HCl-containing deprotection solution. The conversion 18 F-labeledBOC-protected intermediate compounds obtained by radiofluorination of different amounts of BOC-protected stannyl precursor (4, 16 or 8 mg) were subjected to a deprotection reaction in the absence (N) or presence (Y) of ascorbic acid. The results in Table 2 conversion percentages (reflecting the conversion of [18F]fluoride to BOC-protected 6-L- [18F]FDOPA) indicate that the presence of anti-oxidant increases the product yield. Table 2 EXAMPLE 7: Comparative testing of fluorinating agent. Table 3 below illustrates the advantages of using the fluorinating agent [ 18 F]Tetraethylammonium fluoride ([ 18 F]Et4NF) according to a method of the invention as compared to the fluorinating agent as used by Makaravage et al., Org. Lett.2016 Oct 21;18(20):5440-5443, viz. [ 18 F]KF. Moreover, Table 3 shows the advantages of using the copper catalyst of the invention (Cu(Impy) 4 (OTf) 2 ) as compared to the copper catalyst of Makaravage et al., viz. Cu(OTf)2. Furthermore, Makaravage et al. advocate the use of a major excess of pyridine (at least 15 equivalents). By contrast, the method of the invention yields improved results while avoiding the use of pyridine. As such, in experiment 7A pyridine is added in line with Makaravage et al., while in experiment 7B no pyridine is added to the reaction mixture. The results indicated as “Experiment 6” in Table 3 were taken from the final column of Table 1 for ease of reference. For experiments 7A and 7B the following reaction conditions were used. In experiment 7A, the reference catalyst Cu(OTf)2 is used, while in experiment 7B the catalyst of the invention is used. A Waters® Sep-Pak Accell Plus QMA Carbonate Plus Light Cartridge (hereafter: QMA cartridge) was conditioned using 10 mL of ethanol, 10 mL of a 90 mg/ml solution of potassium trifluoromethanesulfonate solution in water, and 10 mL of water. [18F]Fluoride was loaded onto the QMA cartridge and eluted using a solution of 10 mg potassium trifluoromethanesulfonate and 50 µg potassium carbonate in 550 µL water. 1 mL of acetonitrile was added to the eluate and the mixture was dried under vacuum. To the dried mixture was added BOC-protected stannyl precursor N,N,O,O’- tetra-BOC-6-(SnMe 3 )DOPA-OMe (8 mg, 10.3 µmol), 2 eq (20.6 µmol) of the copper catalyst in 1 mL of N,N-dimethylacetamide. In experiment 7A, 15 eq (13 µL) of pyridine was also added, while in experiment 7B no pyridine was added to the reaction mixture. Thereafter, the radiofluorination reaction was performed at 140 °C for 30 minutes. Radio TLC (1:1 EtOAc/hexanes) and subsequent analysis as described in Example 4 were used to determine the conversion of the precursor to BOC-protected 6-L-[ 18 F]FDOPA. The results in Table 3 demonstrate that using the catalyst of the method of the invention improves the conversion, while the addition of pyridine can be avoided. Moreover, using both the catalyst and the fluorinating agent of the method of the invention results in a further improvement of the conversion. Table 3. a Results taken from Table 1. EXAMPLE 8: Disposable cassettes for automated synthesis Cassette A Vessel 1: Et 4 NHCO 3 (5 mg, 26.1 µmol) in 1 mL methanol Vessel 2: BOC-protected stannyl precursor N,N,O,O’-tetra-BOC-6- (SnMe 3 )DOPA-OMe (8 mg, 10.3 µmol) and Cu(Impy) 4 (OTf) 2 (14 mg, 16.7 µmol in 900 µL DMA and 100 µL n-butanol. Vessel 3: 6 M HCl (800 µL, 4.8 mmol) and 0.25 M ascorbic acid solution (200µL, 50 µmol) Vessel 4: HPLC eluent Cassette B Vessel 1: Et4NHCO3 (10 mg, 52.2 µmol) in 1 mL methanol Vessel 2: BOC-protected stannyl precursor N,N,O,O’-tetra-BOC-6- (SnMe 3 )DOPA-OMe (8 mg, 10.3 µmol) and Cu(Impy) 4 (OTf) 2 (14 mg, 16.7 µmol in 900 µL DMA and 100 µL n-butanol. Vessel 3: 6 M HCl (800 µL, 4.8 mmol) and 0.25 M ascorbic acid solution (200µL, 50 µmol) Vessel 4: HPLC eluent Cassette C Vessel 1: Et 4 NHCO 3 (5 mg, 26.1 µmol) in 1 mL methanol Vessel 2: BOC-protected stannyl precursor N,N,O,O’-tetra-BOC-6- (SnMe3)DOPA-OMe (8 mg, 10.3 µmol) in 500 µL DMA. Vessel 3: Cu(Impy) 4 (OTf) 2 (14 mg, 16.7 µmol in 400 µL DMA and 100 µL n-butanol. Vessel 4: 6 M HCl (800 µL, 4.8 mmol) and 0.25 M ascorbic acid solution (200µL, 50 µmol) Cassette D Vessel 1: Et4NHCO3 (5 mg, 26.1 µmol) in 1 mL methanol Vessel 2: BOC-protected stannyl precursor N,N,O,O’-tetra-BOC-6- (SnMe 3 )DOPA-OMe (8 mg, 10.3 µmol) and Cu(Impy) 4 (OTf) 2 (14 mg, 16.7 µmol in 900 µL DMA and 100 µL n-butanol. Vessel 3: 6 M HCl (800 µL, 4.8 mmol) and 0.25 M ascorbic acid solution (200µL, 50 µmol) Vessel 4: Water Cassette E Vessel 1: Et 4 NHCO 3 (5 mg, 26.1 µmol) in 1 mL methanol Vessel 2: BOC-protected stannyl precursor N,N,O,O’-tetra-BOC-6- (SnMe3)DOPA-OMe (8 mg, 10.3 µmol) and Cu(Impy)4(OTf)2 (14 mg, 16.7 µmol in 900 µL DMA and 100 µL n-butanol. Vessel 3: 1 mL 6 M HCl (800 µL, 4.8 mmol) Vessel 4: HPLC Eluent Cassette F Vessel 1: Et4NHCO3 (5 mg, 26.1 µmol) in 1 mL methanol Vessel 2: BOC-protected stannyl precursor N,N,O,O’-tetra-BOC-6- (SnMe 3 )DOPA-OMe (8 mg, 10.3 µmol) and Cu(Impy) 4 (OTf) 2 (14 mg, 16.7 µmol in 900 µL DMA and 100 µL n-butanol. Vessel 3: 4 M HCl (800 µL, 3.2 mmol) and 0.25 M ascorbic acid solution (200µL, 50 µmol) Vessel 4: HPLC Eluent Cassette G Vessel 1: Et4NHCO3 (5 mg, 26.1 µmol) in 1 mL methanol Vessel 2: BOC-protected stannyl precursor N,N,O,O’-tetra-BOC-6- (SnMe 3 )DOPA-OMe (8 mg, 10.3 µmol) and Cu(Impy) 4 (OTf) 2 (14 mg, 16.7 µmol in 900 µL DMF and 100 µL n-butanol. Vessel 3: 6 M HCl (800 µL, 4.8 mmol) and 0.25 M ascorbic acid solution (200µL, 50 µmol) Vessel 4: HPLC Eluent
Next Patent: GELATIN-FREE MOUSSE